Pharmacy Department, Tianjin 4th Center Hospital, Tianjin 300140, China; Central Laboratory, Tianjin 4th Center Hospital, Tianjin 300140, China; Tianjin Fourth Central Hospital, Tianjin 300140, China.
Pharmacy Department, Tianjin 4th Center Hospital, Tianjin 300140, China; Hospital Acquired Infection Control Department, Tianjin 4th Center Hospital, Tianjin 300140, China; Tianjin Fourth Central Hospital, Tianjin 300140, China.
Clin Biochem. 2020 Aug;82:40-50. doi: 10.1016/j.clinbiochem.2020.03.007. Epub 2020 Mar 16.
Diabetes mellitus (DM) and metabolic syndrome (MetS) are systemic metabolic disorders, which have risk factors for diabetic cardiovascular and cerebral microvascular disease. It is very important to screen the metabolic biomarkers between DM and MetS patients, which can make patients benefit to a greater extent and prevent the occurrence of disease in advance.
Diabetes mellitus (DM) and metabolic syndrome are a complex, chronic illness with a pronounced impact on the quality of life of many people. However, understanding the metabolic changes in patients and identifying high-risk individuals is crucial for prevention and disease management strategies.
In this study, a nontargeted metabolomics approach based on UPLC-Q-TOF/MS was used to find the differential metabolites in serum samples from patients with DM and MetS.
Metabonomic analysis reveals metabolic differences between DM and HC with significant differences more than 60 metabolites. While, more than 65 metabolites have significant differences between MetS and HC. The independent disturbed pathway in the DM group was the FoxO signaling pathway. The independent disturbed pathways in the MetS group were the alpha-linolenic acid metabolism, glycerophospholipid metabolism and pyrimidine metabolism. The independent disturbed metabolites and the logistic regression result showed that betaine, alpha-linolenic acid, d-mannose, l-glutamine and methylmalonic acid can be used as a combinatorial biomarker to distinguish DM from healthy control. L-isoleucine, l-glutamine, PC(16:0/16:0), alpha-d-glucose, ketoisocaproic acid, d-mannose, uridine can be used as a combinatorial biomarker in MetS.
Our findings, on one hand, provide critical insight into the pathological mechanism of DM and MetS. On the other hand, supply a combinatorial biomarker to aid the diagnosis of diseases in clinical usage.
糖尿病（DM）和代谢综合征（MetS）是全身性代谢紊乱，存在糖尿病心血管和脑微血管疾病的风险因素。筛选 DM 和 MetS 患者之间的代谢生物标志物非常重要，可以使患者更大程度地受益，并提前预防疾病的发生。
糖尿病（DM）和代谢综合征是一种复杂的、慢性疾病，对许多人的生活质量有明显影响。然而，了解患者的代谢变化并识别高危个体对于预防和疾病管理策略至关重要。
本研究采用基于 UPLC-Q-TOF/MS 的非靶向代谢组学方法，寻找 DM 和 MetS 患者血清样本中的差异代谢物。
代谢组学分析揭示了 DM 和 HC 之间的代谢差异，差异代谢物超过 60 种。而 MetS 和 HC 之间的差异代谢物则超过 65 种。DM 组独立失调的通路是 FoxO 信号通路。MetS 组独立失调的通路是α-亚麻酸代谢、甘油磷脂代谢和嘧啶代谢。独立失调的代谢物和逻辑回归结果表明，甜菜碱、α-亚麻酸、D-甘露糖、L-谷氨酰胺和甲基丙二酸可作为区分 DM 与健康对照的组合生物标志物。L-异亮氨酸、L-谷氨酰胺、PC（16:0/16:0）、α-D-葡萄糖、酮异己酸、D-甘露糖、尿苷可作为 MetS 的组合生物标志物。
我们的研究结果一方面提供了对 DM 和 MetS 病理机制的重要见解，另一方面为临床应用提供了一种组合生物标志物，以辅助疾病的诊断。
